Oxytocin

What Oxytocin does

Oxytocin is a hormone used in hospitals to stimulate labour and control bleeding after birth. Larger nasal-spray trials found no benefit over placebo for social functioning in children with autism or weight loss in adults with obesity. Injection and nasal doses are not interchangeable. Too much can cause dangerous contractions, heart effects or low sodium.

• Pitocin is approved as a hospital injection to start or help labour and to control bleeding after birth. (Drug label)
• In a study of 29 couples, some measures of orgasm improved with nasal oxytocin, though desire and arousal did not change. (Studied in a trial)
• In a trial in people with frontotemporal dementia, on-and-off nasal doses slightly reduced apathy. (Studied in a trial)
• One user reported less social anxiety and another less dislike of being touched; others noticed little effect. (Reported by users)

Uses in the sources

• Approved hospital injections start or support medically indicated labour, aid selected abortion care and control bleeding after birth. (Drug label) (source)
• Nasal oxytocin has been studied for autism. Large trials and the 2026 pooled review found no reliable overall social benefit. (Studied in a trial) (source)
• Acute studies sometimes reduce one meal. The larger 8-week trial found +0.20 kg with oxytocin versus +0.26 kg with placebo. (Studied in a trial) (source)
• A 29-couple study found no change in drive, arousal, erection or lubrication. Some subjective orgasm measures improved. (Studied in a trial) (source)
• Studied for feeding in Prader-Willi syndrome and apathy in frontotemporal dementia. Benefits were limited to selected outcomes. (Studied in a trial) (source)
• People report nasal sprays and injections for bonding, mood or sleep. Reports include no effect, flushing and severe nausea or dizziness. (Reported by users) (source)

Oxytocin dosage

Typical reported dose: 25–100 mcg per injection, timing varies

• Pitocin: supervised labour infusion: Start 0.5–1 mU/min; increase by 1–2 mU/min every 30–60 minutes to the desired contraction pattern., then At 5–6 cm dilation, the rate may be reduced by similar increments. continuous infusion; adjust every 30–60 minutes, into a vein. Drug label. Studied in: Hospital obstetric patients. (source)
• Pitocin: bleeding after birth, IV: 10–40 units added to the running IV fluid; maximum 40 units per 1000 mL. Adjust rate to control uterine atony. continuous infusion adjusted to uterine response, into a vein. Drug label. Studied in: Hospital postpartum patients. (source)
• Pitocin: bleeding after birth, IM: 10 units (1 mL) intramuscularly after delivery of the placenta. one dose after delivery of the placenta, into muscle. Drug label. Studied in: Postpartum patients after placental delivery. (source)
• Pitocin: infusion after curettage: 10 units in 500 mL physiologic saline or 5% dextrose-in-water to support uterine contraction after curettage. infusion; rate individualized, into a vein. Drug label. Studied in: Patients after curettage for incomplete, inevitable or elective abortion. (source)
• Pitocin: midtrimester abortion infusion: 10–20 milliunits/minute; total dose must not exceed 30 units in 12 hours. continuous infusion; total capped over 12 hours, into a vein. Drug label. Studied in: Patients after intra-amniotic treatment for midtrimester abortion. (source)
• WHO: prevent bleeding after birth: 10 IU intramuscularly for postpartum-haemorrhage prevention. one preventive dose, into muscle. Clinician-published. Studied in: Women giving birth under skilled care. (source)

Highest studied: Highest located daily human regimen: 2.5 IU/day, about 4.2 mcg, in a weak 1953 engorgement trial..

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to store Oxytocin

Comes as: Ready-to-use 10 units/mL injection solution in 1 mL single-dose vials., 10 mL multiple-dose Pitocin vials, containing 100 units total..

Mixed with: Pitocin labour infusion: 10 units in 1000 mL of 0.9% sodium chloride or lactated Ringer’s, giving 10 milliunits/mL..

• Approved injections come dissolved. For infusion, they are diluted, not mixed from powder.
• The UK product has 48-hour chemical/physical stability at 25°C after dilution; microbial limits are shorter.
• Powder-vial and home-spray mixing reports are kept in the community records, outside these label handling instructions.

Before mixing: Pitocin: 20–25°C. The checked UK ampoule: 2–8°C, protected from light; up to 30°C for 3 months, then discard.

After mixing: UK diluted infusion: use immediately; normally no longer than 24 hours at 2–8°C unless aseptic conditions are validated. This is not a home-spray shelf life.

UK Esteve oxytocin 10 IU/mL infusion ampoules: refrigerate at 2-8 C in the carton, protected from light. Use diluted infusions immediately; any delay normally must stay within 24 hours at 2-8 C unless prepared under validated sterile conditions.

Oxytocin side effects and risks

Reported side effects

• Nasal discomfort or irritation: 8 week obesity trial: 6/31 (19.4%) vs 2/30 (6.7%) placebo., mild. Report persistent irritation or nosebleeds; review the formulation and delivery device. (source)
• Drowsiness: Single dose meal trial: 6/25 oxytocin sessions vs 4/25 placebo sessions., mild. Avoid driving if sleepy; severe sedation needs review. (source)
• Stomach or bowel symptoms: Obesity trial organ class events: 5/31 (16.1%) vs 8/30 (26.7%); not a rate for nausea alone., moderate. Review persistent nausea, vomiting or bowel symptoms with a clinician. (source)
• Restlessness or behaviour changes: SOARS B: restlessness 8% vs 2% placebo; increased appetite 16% vs 10%., moderate. Stop escalation and review agitation, aggression or sleep changes. (source)
• Headache: One moderate headache among 31 oxytocin participants in the obesity trial; overall headache rate unavailable., moderate. A severe headache with confusion, vomiting or weakness needs urgent assessment. (source)
• Low sodium or water intoxication: Seizures, coma and deaths are reported with prolonged high dose IV infusion; rates are unknown., serious. Stop exposure and get emergency care for confusion or seizures. (source)
• Fast heart rate (UK IV product): UK IV label: tachycardia is common (≥1/100 to <1/10). This is not a nasal use frequency., serious. Chest pain, fainting or a racing/irregular heartbeat need urgent care. (source)
• Slow heart rate (UK IV product): UK IV label: bradycardia is common (≥1/100 to <1/10). This is not a nasal use frequency., serious. Chest pain, fainting or a racing/irregular heartbeat need urgent care. (source)
• Abnormal heart rhythm (UK IV product): UK IV label: arrhythmia is uncommon (≥1/1,000 to <1/100). This is not a nasal use frequency., serious. Chest pain, fainting or a racing/irregular heartbeat need urgent care. (source)
• Low blood pressure (UK IV product): UK IV label: hypotension has unknown frequency. This is not a nasal use frequency., serious. Chest pain, fainting or a racing/irregular heartbeat need urgent care. (source)
• High blood pressure (US Pitocin injection): US Pitocin injection label reports high blood pressure without a rate; the nasal use rate is unknown., serious. Chest pain, fainting or a racing/irregular heartbeat need urgent care. (source)
• Excessive uterine contractions or rupture: Reported in pregnancy and birth care; excessive dosing or a sensitive/scarred uterus raises risk., serious. Hospital staff stop the infusion for excessive contractions or a baby in distress. (source)
• Severe allergic reaction: unknown, serious. Call emergency services for swelling, breathing trouble or collapse. Latex allergy may increase risk. (source)
• Temporary breast enlargement: One oxytocin participant in the 106 person adult autism trial., moderate. Review new breast changes or discharge. (source)

Stop and get help if

• Confusion, severe headache, repeated vomiting, a seizure or unusual drowsiness: Stop oxytocin and get urgent care for possible low sodium or water intoxication.
• Chest pain, fainting, severe breathlessness or a racing/irregular heartbeat: Stop oxytocin and seek emergency care.
• Swollen tongue or face, hives with breathing trouble, or collapse: Call emergency services for a possible severe allergic reaction.
• Severe pelvic pain, nonstop contractions or heavy vaginal bleeding: Seek emergency obstetric care, especially if pregnancy is possible.

Who should avoid it

• pregnant: Unsupervised use in pregnancy risks uterine contractions and fetal harm. Hospital birth care is a separate approved indication with medical monitoring.
• breastfeeding: Obstetric use and supervised lactation research are separate; this is not a claim of proven infant toxicity.
• tryingToConceive: Precaution for use on your own: fertility and early-pregnancy safety are unknown.
• under18: Pediatric studies are evidence records and do not authorize home use.
• hormoneSensitiveCancer: Precaution outside birth care: long-term cancer and fertility safety are unknown. Hormone-sensitive cancer is not a labelled contraindication.
• other: Known allergy to oxytocin or its ingredients is a label contraindication.
• other: Latex allergy has been linked to anaphylaxis after oxytocin; alert the clinical team.
• other: Water retention can worsen it.
• other: Labels rule out labour use with unsafe vaginal birth, excessive contractions, obstructed labour or a baby in distress.
• other: A prior caesarean or major surgery on the uterus or cervix raises the risk of the uterus tearing during labour infusion.
• heartCondition: Blood pressure, heart rhythm and coronary blood flow can change. Long QT is a specific concern.
• uncontrolledBloodPressure: Severe blood-pressure changes have occurred with injected oxytocin and interacting drugs.
• kidneyDisease: Severe kidney impairment can increase water retention and possible oxytocin accumulation.
• seizureDisorder: Low sodium can cause seizures. A possible seizure also led to withdrawal from a small autism trial.
• psychiatricCondition: Agitation, aggression and temper outbursts have occurred. Nasal oxytocin is not an established mood or anxiety treatment.
• eatingDisorderHistory: Precaution: an eating-disorder history blocks appetite-suppression and fat-loss use. This is not a labelled contraindication.
• surgeryPlanned: Tell the anaesthesia team about use. Anaesthetics, vasoconstrictors and other uterotonics can change oxytocin effects.
• testedAthlete: Oxytocin is not specifically prohibited in the 2026 list. IV volume rules and other ingredients in a combination still matter.
• other: The UK IV product label contraindicates oxytocin within 6 hours after vaginal prostaglandins. This block requires both the vaginal exposure and the timing condition.
• other: Pitocin's boxed warning says it is not for starting labour without medical reasons. Benefits versus risks remain unknown.

Interactions

• Other oxytocin products and uterotonics: Combining these drugs may add to contraction and circulation effects. Use during childbirth needs specialist care.
• Prostaglandins used in obstetrics: Prostaglandins and their analogues can strengthen uterine contractions with IV oxytocin. The separate block applies within 6 hours after vaginal use.
• Drugs that prolong QT: Oxytocin can cause an irregular heartbeat. Drugs that delay the heart's electrical recovery, called QT prolongation, add risk.
• Vasoconstrictors and sympathomimetics: Oxytocin may further raise blood pressure. Severe increases were reported after a vasoconstrictor was used with an anaesthetic block near the tailbone.
• Inhaled anaesthetics: These drugs can weaken uterine contractions and cause unexpected blood-pressure changes or irregular heartbeats with oxytocin.
• Desmopressin and other water-retaining drugs: Water-retaining effects may add. A hypothalamic-obesity trial checked sodium and adjusted desmopressin; it did not prove a safe combination.
• Insulin and sulfonylureas: One acute study changed insulin sensitivity. A clinical interaction or added low-sugar rate has not been established.

Product quality risks

• A review of 559 nonrandomly sampled oxytocin products in 15 lower-income countries found 36% outside the 90–110% content specification.
• Those findings concerned medical supply chains; they do not estimate failure rates for online peptide vials.
• Poor cold-chain control can lower oxytocin content and increase breakdown products. Storage rules depend on the exact product.
• Compounded or unregulated preparations can have wrong strength or contamination; a purity percentage does not prove sterility.

What to expect

Approved Pitocin use is short-term care around childbirth, with treatment length set by the hospital team.

A 2011 review covered 38 separate nasal-spray trials. This is a minimum count that leaves out later research and childbirth trials.

Key studies

• Preventing bleeding after birth: Preventive oxytocin reduced bleeding versus placebo or no uterotonic. (source)
• Cochrane update: 122 birth trials: The updated birth-prevention review supports oxytocin as a standard comparator. (source)
• Trust in a laboratory game: A laboratory trust effect helped launch social-cognition research. (source)
• Adults with autism: 6 weeks: Primary outcomes were negative; some secondary measures improved. (source)
• Adult autism crossover: 6 weeks: A small crossover trial found better social-reciprocity scores. (source)
• Autism dose finding: 16 or 32 IU/day: Neither dose improved the overall trial population. (source)

Oxytocin FAQ

• Is Oxytocin FDA-approved? No. Injection approval does not cover nasal, under-the-tongue, mood, autism or weight-loss products. Compounded drugs are not FDA-approved.
• How do people take it? Under the skin, per injection; interval usually not stated. Source: reported by users, not an established dose.
• Can I take it with Bremelanotide / PT-141? People combine it with nasal oxytocin hoping to improve sexual desire and closeness. No controlled trial of this pairing was located. Combination safety is unknown. Reports cannot separate effects from either ingredient. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? No, it is not on the banned list (WADA 2026). IV infusions/injections above 100 mL per 12 hours are prohibited except during hospital treatment, surgery or clinical diagnostic investigations. M2.2 separately addresses total IV infusions or injections over 100 mL per 12 hours, except legitimate hospital treatment, surgical procedures or clinical diagnostic investigations.
• How do I store it once opened? UK diluted infusion: use immediately; normally no longer than 24 hours at 2–8°C unless aseptic conditions are validated. This is not a home-spray shelf life.